Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
San Diego Cardiac Center
101
mi
from 91732
San Diego, CA
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
San Diego Cardiac Center
101
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
Texas Cardiac Arrythmia Research Foundation
1212
mi
from 91732
Austin, TX
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
Texas Cardiac Arrythmia Research Foundation
1212
mi
from 91732
Austin, TX
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
Houston Methodist
1357
mi
from 91732
Houston, TX
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
Houston Methodist
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
Houston VAMC
1358
mi
from 91732
Houston, TX
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
Houston VAMC
1358
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
Arizona Heart Rhythm Center
1722
mi
from 91732
Phoenix, AZ
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
Arizona Heart Rhythm Center
1722
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
USC Los Angeles - Keck Hopsital
10
mi
from 91732
Los Angeles, CA
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
USC Los Angeles - Keck Hopsital
10
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital
1922
mi
from 91732
Atlanta, GA
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University
2269
mi
from 91732
Richmond, VA
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
University of Colorado School of Medicince, Denver
mi
from 91732
Denver, CO
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
University of Colorado School of Medicince, Denver
mi
from 91732
Denver, CO
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
KUMC Research Institute
mi
from 91732
Kansas City, KA
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
KUMC Research Institute
mi
from 91732
Kansas City, KA
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
St. Luke's Hospital Duluth
1610
mi
from 91732
Duluth, MN
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
St. Luke's Hospital Duluth
1610
mi
from 91732
Duluth, MN
Click here to add this to my saved trials
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated:  12/31/1969
BCM/CHI St. Luke's Hospital
mi
from 91732
Houston, TX
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Status: Enrolling
Updated: 12/31/1969
BCM/CHI St. Luke's Hospital
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2309
mi
from 91732
Boynton Beach, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2309
mi
from 91732
Boynton Beach, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
356
mi
from 91732
Chandler, AZ
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
356
mi
from 91732
Chandler, AZ
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
363
mi
from 91732
Gilbert, AZ
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
363
mi
from 91732
Gilbert, AZ
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
14
mi
from 91732
Glendale, AZ
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
14
mi
from 91732
Glendale, AZ
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
427
mi
from 91732
Tucson, AZ
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1463
mi
from 91732
Little Rock, AR
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1463
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
21
mi
from 91732
North Hollywood, CA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
21
mi
from 91732
North Hollywood, CA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
24
mi
from 91732
Santa Ana, CA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
24
mi
from 91732
Santa Ana, CA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
397
mi
from 91732
Santa Rosa, CA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
397
mi
from 91732
Santa Rosa, CA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
50
mi
from 91732
Thousand Oaks, CA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
50
mi
from 91732
Thousand Oaks, CA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
24
mi
from 91732
Torrance, CA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
24
mi
from 91732
Torrance, CA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
25
mi
from 91732
Tustin, CA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
25
mi
from 91732
Tustin, CA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
70
mi
from 91732
Ventura, CA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
70
mi
from 91732
Ventura, CA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
804
mi
from 91732
Colorado Springs, CO
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
804
mi
from 91732
Colorado Springs, CO
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2117
mi
from 91732
Clearwater, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2117
mi
from 91732
Clearwater, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2304
mi
from 91732
Delray Beach, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2304
mi
from 91732
Delray Beach, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2315
mi
from 91732
Hialeah, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2315
mi
from 91732
Hialeah, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2127
mi
from 91732
Jacksonville, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2127
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2310
mi
from 91732
Lauderdale Lakes, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2310
mi
from 91732
Lauderdale Lakes, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2321
mi
from 91732
Miami, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2321
mi
from 91732
Miami, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2314
mi
from 91732
Oakland Park, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2314
mi
from 91732
Oakland Park, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2182
mi
from 91732
Orlando, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2182
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2183
mi
from 91732
Ormond Beach, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2183
mi
from 91732
Ormond Beach, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2117
mi
from 91732
Palm Harbor, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2117
mi
from 91732
Palm Harbor, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2153
mi
from 91732
Plant City, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2153
mi
from 91732
Plant City, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2148
mi
from 91732
Sarasota, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2148
mi
from 91732
Sarasota, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2176
mi
from 91732
Winter Haven, FL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2176
mi
from 91732
Winter Haven, FL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1939
mi
from 91732
Lawrenceville, GA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1939
mi
from 91732
Lawrenceville, GA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1819
mi
from 91732
Anderson, IN
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1819
mi
from 91732
Anderson, IN
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1780
mi
from 91732
Avon, IN
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1780
mi
from 91732
Avon, IN
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1715
mi
from 91732
Evansville, IN
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1715
mi
from 91732
Evansville, IN
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1797
mi
from 91732
Franklin, IN
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1797
mi
from 91732
Franklin, IN
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1756
mi
from 91732
Valparaiso, IN
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1756
mi
from 91732
Valparaiso, IN
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1303
mi
from 91732
Council Bluffs, IA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1303
mi
from 91732
Council Bluffs, IA
Click here to add this to my saved trials